Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed Plc LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 286.00p 53,225 08:00:00
Bid Price Offer Price High Price Low Price Open Price
282.00p 290.00p 286.00p 286.00p 286.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 54.11 -10.77 -20.00 133.1

Ergomed (ERGO) Latest News (2)

More Ergomed News
Ergomed Takeover Rumours

Ergomed (ERGO) Share Charts

1 Year Ergomed Chart

1 Year Ergomed Chart

1 Month Ergomed Chart

1 Month Ergomed Chart

Intraday Ergomed Chart

Intraday Ergomed Chart

Ergomed (ERGO) Discussions and Chat

Ergomed Forums and Chat

Date Time Title Posts
13/6/201910:15Ergomed PLC304
06/7/201621:28Stephen Stamp, CFO of Ergomed (ERGO)-

Add a New Thread

Ergomed (ERGO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Ergomed trades in real-time

Ergomed (ERGO) Top Chat Posts

Ergomed Daily Update: Ergomed Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ERGO. The last closing price for Ergomed was 286p.
Ergomed Plc has a 4 week average price of 219p and a 12 week average price of 166p.
The 1 year high share price is 286p while the 1 year low share price is currently 142.50p.
There are currently 46,540,248 shares in issue and the average daily traded volume is 139,097 shares. The market capitalisation of Ergomed Plc is £133,105,109.28.
jamtomorrow2: Interesting that Cel-Sci’s share price has doubled recently on optimism that Multikine’s trial will be successful. Ergomed has an interest in this drug.
sicilian_kan: Seems completely overdone to me. - 5% reduction in revenue compared to market consensus, yet a 33% reduction in share price. - 2018 EBITDA still going to be ahead of 2017's £2.8m - Backlog of contracts still strong and increase on last years - The Company's cash position remains strong with positive cash flows in the period. I have only a small amount here. Invested 18 months ago on a 5 year basis. See no reason to bail out. Strategy and management still seem strong and am excited by the pharmacovigilance opportunities.
douglas fir: EQUITY DEVELOPMENT EQUITY DEVELOPMENT CHAMPIONING GROWTH COMPANIES Ergomed : Positive PeproStat Data Symbol ERGO Listing AIM Share Price 210p Market Cap £89.6m Sector Healthcare Published 01/11/17 Analyst Elizabeth Klein Recently announced results from the phase II clinical trial of PeproStat were positive. As a result, the probability of PeproStat reaching the market increased from around a third to around two-thirds. This adds £12.7m to the valuation of this programme. As expected the shares saw strong performance on the back of the positive data. There remains significant upside to the bottom end of our 276p-401p valuation. Ergomed acquired Haemostatix in May 2016 for £28m (an initial £8.0m upfront, with the remainder in success-based milestone payments). Haemostatix had developed a new approach to controlling bleeding using a peptide that binds to fibrinogen, targeting a surgical market valued at c. US$2.5bn, growing at c. 6.2% pa. The phase II trial consisted of 169 patients treated (162 evaluable) at 16 sites in five European countries. PeproStat was shown to be clinically and significantly superior to standard of care across three surgery types. The mean time to Haemostasis was reduced by 1.55 minutes for PeproStat vs. standard of care, and favourable by investigator opinion (80.9% surgeons rated PeproStat (blinded) as good to excellent in controlling bleeding vs 59.6% for standard of care). The first commercial deal for a Haemsotatix product was signed late September with a South Korean company, Boryung Pharmaceutical Co. Ergomed will receive an upfront payment and a series of milestone payments as well as a double-digit share of all future product sales in this territory. Further PeproStat deals, along with the start of the next trial in H2 2018 and initial ReadyFlow data, should feature in the news flow over the next 12-18 months, along with further acquisitions to boost the profitability of the Services business. The bottom of the 276p - 401p per share valuation is based on the more conservative “Services-only” sales forecast, discounting completely the potential upside from Development projects. The top of the range adds in these projects with the Haeomstatix programme now making up 60% of the Development valuation.
timbo003: Re: post #208 The current market cap is £84, so if the phase III study were to start with the share price where is is now, presumably the milestone (equivalent to around 16p/share) would not be payable, if the share price were to rise to around 245p/share, then it would be payable. That suggests to me that for now, the maximum upside for the share is around 245p in the absence of any further substantial news.
timbo003: The Leeds seminar is a bit too far for me to travel on Tuesday 13th, so I'll hang on and go along to the AGM instead on Friday 16th June which will be held at 265 the Strand in Central London, I'm not too keen on the 09:30 start time though! I see there has been quite a bit of news from Cel-Sci over the last few days: They submitted yet another response to FDA on June 5th, so we now have another 30 day wait for further FDA feedback. They are also extending the term of some out of the money warrants from June 8, 2017 to July 10, 2017 which are exercisable at $0.18. The current share price is quoted at $0.0997, so someone in the company is hopeful that FDA will relent and let the Head and Neck cancer study recommence.
timbo003: I wonder how long they can carry on without another fund raise? The share price movements today should give us a clue:
timbo003: The share price action isn't giving much away, up around 4% on the day
bermudashorts: Timbo, As always thanks very much for taking the time and trouble to share another comprehensive report. Lucky escape indeed,which sort of brings me to my question. Do you have any concerns regarding the drive on the co-development front? 10 ongoing projects at any one point in time is quite a commitment and not without risk. 2 or 3 failures in a row could be quite damaging. I should add, not necessarily in financial terms but in regards to sentiment. I guess time will tell and it only takes one or two successes to validate the strategy. Meanwhile the share price continues to go from strength to strength. As I posted over on LSE, I wish the 3 month chart for the rest of my portfolio looked like this.
timbo003: I'm not invested here but they are on my watch list and I attended the ShareSoc presentation yesterday so thought I would do a few notes as an aid memoire. This is the second time I have seen them present in the last year, so some of the slides were familiar. Steve Stamp (CFO) gave the presentation (unfortunately there were no slide handouts so I cannot vouch for accuracy of numbers in my notes). Summary details: * Market Cap circa £50M, Revenue around £30M, EBITDA positive * 100+ clients, 300 clinical studies, 50K patients, 350 employees. * Ergomed has an unusual and diversified business model which consists of four main activities (CRO activities, Pharmacovigilance, co-development portfolio and Ergomed development portfolio). CRO activities: This specialises in a small number of areas (oncology, neurology, immunology and rare diseases, they won’t take on programs which require large studies like diabetes or asthma). This is a profitable part of the business but profits recycled to build co-development portfolio of drugs where Ergomed have a shared interest (5-15%) with the trial sponsor. Ergomed are continuing to buy and build the CRO business as small CRO companies can currently be acquired for 8X EBITDA. Pharmacovigilance: This is profitable with a 30-40% gross margin and demand for services is growing with large pharma outsourcing. Once signed up clients are sticky. Ergomed would like to acquire more businesses like this but they are hard to find. Co development portfolio: This currently consists of 5 products, which cost them the equivalent to £3M last year (not sure about previous years), they were acquired through discounting the CRO fee (discount 30 – 50%) with client companies who are using Ergomed as CRO for clinical studies on the 5 compounds (note there used to be 6 compounds one failed). Ergomed receives a fixed percentage of future royalties and milestone payments which are between 5 and 15% (of the partners income from the compound, not from gross sales should the partner outlicence to a large pharma). In some cases the client has negotiated a cap on the total fees/income receivable by Ergomed. Ergomed 100% owned development portfolio: This consists of two products (Haemostatix) to reduce/eliminate bleeding during surgery which sounded quite low tech, basically a biocompatible occlusive liquid and a biocompatible gel which have convenience advantages over existing products. When asked about the relative value assigned by the brokers to the different parts of the business we were told it was £53m for the combined CRO and pharmacovigilance divisions, £15m for the co-development portfolio, £20m for their own Haemostatix development portfolio and £12m cash. The market cap is currently around £50m (share price circa 120p) and the last placing at 140p per share to fund the latest acquisitions was two months ago (May 2016). What I like about the company is the potential royalty stream from the shared interest portfolio and the existing cash generating CRO and Pharmacovigilance service activities. What I don’t particularly like is that they are also diversified into developing their own products (Haemostatix) and I am always suspicious of continuous buy and build strategies, which is what they are doing for the CRO and pharmacovigilance services and it is how they acquired the Haemostatix develop portfolio. These will stay on my watch list for now, I would be more interested if they sold off Haemostatix and concentrated on organic growth rather than buy and build on the services whilst simultaneously growing the value of the co-development portfolio.
rivaldo: Not a holder here, but been watching for a long time puzzled by the share price fall, and now I know the reason. The placing at 140p is fair enough, but imo the entire attraction of this company has been destroyed by today's transaction. I liked the combination of a reasonably low P/E combined with little downside and large upside from the investments in higher-risk drugs via the investment of costs. Today's acquisition commits ERGO to long-term development with no commercialisation until 2020 at the earliest. The "intention for Ergomed to remain profitable at the EBITDA level" is just a sop. The entire rationale for investing has been completely changed. Why couldn't they just continue to do what they were doing? ERGO is uninvestable for me now. It will likely come off my watchlist unless someone/something changes my mind.
Ergomed share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190618 16:50:32